Validation of targets and drug candidates in an engineered three-dimensional cardiac tissue model.
High-throughput target discovery confronts the biopharmaceutical industry with a plethora of target candidates. The validation of these candidates in disease-specific animal models often lacks the required throughput. Here, we discuss perspectives and limitations of a novel engineered three-dimensional cardiac tissue, which enables the influence of gene and drug intervention to be monitored on a cellular and molecular level under physiological conditions in sufficient throughput. The model is an extremely helpful filter to prioritize multiple development candidates before moving a project into large animal models with higher predictivity.
Navé
Barbara T
BT
Department of Research, MediGene AG, Lochhamer Str. 11, 82152 Martinsried, Germany.
Becker
Michael
M
Roenicke
Volker
V
Henkel
Thomas
T
D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006321:Heart / Q000033:anatomy & histology* / Q000187:drug effects*; D006801:Humans; D008953:Models, Anatomic; D009206:Myocardium / Q000166:cytology; D015203:Reproducibility of Results
D002317:Cardiovascular Agents